Final Nano Risk Framework Released
NTP Board of Scientific Counselors Reviews Nomination of Nanoscale Silver for Testing
Nano-Bio Interaction Workshop Materials Available
EHP-in-Press Publishes Study Regarding Pharmacokinetics of Quantum Dots
FDA Announces New Advisory Committee to Address Risk Communication
On June 4, 2007, the Food and Drug Administration (FDA) announced a new advisory committee intended to counsel FDA on how to strengthen the communication of risks and benefits of FDA-regulated products to the public. The Risk Communication Advisory Committee will:
- Help FDA better understand the communication needs and priorities of the general public;
- Advise FDA on the development of strategic plans to communicate product risks and benefits; and
- Make recommendations to FDA on what current research suggests about crafting risk and benefit messages, as well as how to most effectively communicate specific product information to vulnerable audiences.
Congressional Nanotechnology Caucus Will Host Nanotechnology and Energy Events
Study Recommends Amendments to EU Legislation to Address Nanomaterials
The July 2007 issue of Regulatory Toxicology and Pharmacology includes an article entitled “Limits and Prospects of the ‘Incremental Approach’ and the European Legislation on the Management of Risks Related to Nanomaterials.” According to the authors, the European Commission (EC) has adopted an incremental approach, focusing on adopting existing laws to regulate nanotechnologies. The authors concluded that the current regulations fail to address the environmental, health, and safety risks posed by nanomaterials and recommended specific revisions to European regulatory policies and the information on which they are based.
Continue Reading...